Covered recipient · General Payments record
CHRISTOPHER MICHAEL PIECZONKA
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$221,773.60
216 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,172.46 | 29 |
| Consulting Fee | $92,996.81 | 22 |
| Travel and Lodging | $12,980.83 | 35 |
| Food and Beverage | $6,021.44 | 127 |
| Honoraria | $2,500.00 | 1 |
| Education | $102.06 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHRISTOPHER MICHAEL PIECZONKA
NPI 1376530121 · CMS profile ID 333859
Allopathic & Osteopathic Physicians / Urology
SYRACUSE, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376530121?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376530121?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376530121?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- CHRISTOPHER MICHAEL PIECZONKA, NPI 1376530121, CMS profile ID 333859, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1376530121?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
216 matching records · $221,773.60 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 216.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| IMMUNITYBIO, INC. | $21.68 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233178463 | CMS |
| Janssen Biotech, Inc. | $187.69 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269223 | CMS |
| ABBVIE INC. | $28.43 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203618345 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $124.42 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705653 | CMS |
| Janssen Biotech, Inc. | $64.47 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268511 | CMS |
| Janssen Biotech, Inc. | $118.05 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269241 | CMS |
| Procept Biorobotics Corporation | $135.75 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249760203 | CMS |
| Janssen Biotech, Inc. | $6,075.00 | 09/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174270014 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $27.47 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705628 | CMS |
| Janssen Biotech, Inc. | $216.60 | 09/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268580 | CMS |
| Janssen Biotech, Inc. | $2,430.00 | 09/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269703 | CMS |
| Janssen Biotech, Inc. | $124.99 | 09/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174270107 | CMS |
| ACCORD HEALTHCARE, INC. | $17.25 | 09/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248747337 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $5,513.00 | 09/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705649 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $727.50 | 09/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705632 | CMS |
| Astellas Pharma US Inc | $24.30 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238662287 | CMS |
| Verity Pharmaceuticals Inc. | $24.18 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234196258 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $348.19 | 09/13/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705637 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $1,597.97 | 09/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705646 | CMS |
| Janssen Biotech, Inc. | $216.13 | 09/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269589 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,687.50 | 09/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215346669 | CMS |
| Novartis Pharmaceuticals Corporation | $2.54 | 09/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200728906 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $18.71 | 09/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250982706 | CMS |
| ACCORD HEALTHCARE, INC. | $22.00 | 09/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248744703 | CMS |
| AstraZeneca Pharmaceuticals LP | $160.50 | 09/05/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214780311 | CMS |
| IMMUNITYBIO, INC. | $1,900.00 | 09/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233177883 | CMS |
| Janssen Biotech, Inc. | $330.00 | 09/03/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269472 | CMS |
| Janssen Biotech, Inc. | $23.40 | 08/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269659 | CMS |
| PFIZER INC. | $15.18 | 08/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229489385 | CMS |
| Telix Pharmaceuticals | $13.92 | 08/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189637161 | CMS |
| Janssen Biotech, Inc. | $6,075.00 | 08/14/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269312 | CMS |
| Astellas Pharma US Inc | $26.57 | 08/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238776018 | CMS |
| Janssen Biotech, Inc. | $990.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268911 | CMS |
| Janssen Biotech, Inc. | $470.08 | 08/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269343 | CMS |
| Janssen Biotech, Inc. | $165.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269912 | CMS |
| Janssen Biotech, Inc. | $215.60 | 08/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268753 | CMS |
| Janssen Biotech, Inc. | $5.50 | 08/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174270125 | CMS |
| Dendreon Pharmaceuticals LLC | $21.87 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245008372 | CMS |
| Merck Sharp & Dohme LLC | $25.50 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238182005 | CMS |
| PFIZER INC. | $18.23 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229164018 | CMS |
| BIOPROTECT MEDICAL, INC. | $17.44 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252500494 | CMS |
| Janssen Biotech, Inc. | $480.24 | 07/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268505 | CMS |
| Janssen Biotech, Inc. | $6,075.00 | 07/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269355 | CMS |
| Janssen Biotech, Inc. | $295.80 | 07/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268783 | CMS |
| Janssen Biotech, Inc. | $397.70 | 07/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174270088 | CMS |
| PFIZER INC. | $11.45 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228966900 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $30.01 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225705611 | CMS |
| Janssen Biotech, Inc. | $30.50 | 07/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174268922 | CMS |
| Janssen Biotech, Inc. | $313.66 | 07/17/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269085 | CMS |
| Janssen Biotech, Inc. | $25.97 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174269323 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $53,652.45 | 43 |
| PY2025 | Principal investigator | $6,436,553.89 | 492 |
| PY2024 | Recipient | $3,980.00 | 2 |
| PY2024 | Principal investigator | $6,175,115.62 | 421 |
| PY2023 | Recipient | $6,643.62 | 11 |
| PY2023 | Principal investigator | $3,550,725.72 | 347 |
| PY2022 | Principal investigator | $3,987,429.31 | 448 |
| PY2021 | Recipient | $897.03 | 3 |
| PY2021 | Principal investigator | $3,344,765.27 | 235 |
| PY2020 | Recipient | $3,575.77 | 2 |
| PY2020 | Principal investigator | $5,032,788.13 | 326 |
| PY2019 | Recipient | $2,074.96 | 1 |
| PY2019 | Principal investigator | $1,896,669.41 | 291 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
535 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,129.43 | 12/31/2025 | Non-covered Recipient Entity Associated Medical Professionals URO | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232925153 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,076.30 | 12/31/2025 | Non-covered Recipient Entity Associated Medical Professionals of NY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926737 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,322.38 | 12/31/2025 | Non-covered Recipient Entity Associated Medical Professionals of NY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927929 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,650.83 | 12/31/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,087.00 | 12/29/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175336413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,561.00 | 12/29/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336820 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,346.00 | 12/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337197 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/25/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725826 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 12/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228741077 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 12/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228747359 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 12/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228748777 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,621.00 | 12/22/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $650.00 | 12/22/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336429 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 12/22/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,168.00 | 12/22/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336994 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,350.00 | 12/22/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $194.00 | 12/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175336324 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 12/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175337142 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,707.00 | 12/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,266.00 | 12/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175337318 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,135.00 | 12/17/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 12/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $113,000.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175336455 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336722 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,988.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175337114 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,802.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175337181 |
| Principal investigator 1 | Janssen Research & Development, LLC | $825.00 | 12/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,242.00 | 12/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,950.00 | 12/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 12/09/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 12/09/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247985 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 12/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,202.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336391 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,692.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336461 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,155.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336526 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,718.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52,298.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,632.00 | 12/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175337374 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,500.00 | 11/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 11/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 11/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 11/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175337326 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $520.00 | 11/27/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,097.00 | 11/27/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336231 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,394.00 | 11/26/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175248016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175336275 |
| Principal investigator 1 | Janssen Research & Development, LLC | $194.00 | 11/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175336292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,988.00 | 11/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175337382 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $153,099.65 | 11/21/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, PLLC | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235998860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,486.00 | 11/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336208 |
| Principal investigator 1 | Janssen Research & Development, LLC | $53,304.00 | 11/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336729 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,270.00 | 11/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 11/20/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175336856 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,976.00 | 11/20/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175337280 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175337404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,976.00 | 11/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175336300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 11/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175337108 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175337242 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/17/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726456 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $1,000.00 | 11/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230648 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/15/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727235 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 11/14/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409854 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 11/14/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 11/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 11/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247782 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 11/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247831 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 11/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247920 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,621.00 | 11/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,542.00 | 11/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,626.00 | 11/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337248 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $812.50 | 11/12/2025 | Non-covered Recipient Entity Associated Medical Professionals Of NY PLLC Admin | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,519.00 | 11/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336397 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892512 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892540 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892566 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,520.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892578 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,920.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892585 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892589 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892593 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,920.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892596 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,720.00 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892600 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $1,753.50 | 11/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242061273 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 11/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739517 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 11/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739800 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 11/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228741009 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,246.00 | 11/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,034.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336578 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,005.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175336599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175337043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,504.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175337426 |
| Principal investigator 1 | Janssen Research & Development, LLC | $159.00 | 11/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175337434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,964.00 | 10/30/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175336199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,744.00 | 10/30/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175336354 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,787.68 | 10/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 10/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247913 |
| Principal investigator 1 | PFIZER INC. | $184,831.55 | 10/27/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727075 |
| Principal investigator 1 | PFIZER INC. | $184,831.55 | 10/26/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727025 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $810.00 | 10/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409978 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,025.00 | 10/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410240 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,500.00 | 10/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410252 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 10/23/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $948.00 | 10/23/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247956 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 10/23/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248023 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 10/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175337164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,150.00 | 10/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175337018 |
| Principal investigator 1 | MEDIVATION LLC. | $300.00 | 10/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228747906 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 10/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175248066 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 10/15/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410004 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $2,630.25 | 10/14/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242061163 |
| Principal investigator 1 | Janssen Research & Development, LLC | $53,304.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336362 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336509 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,097.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,983.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,307.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,670.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,733.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337205 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,380.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 10/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175337452 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,812.50 | 10/10/2025 | Non-covered Recipient Entity Associated Medical Professionals Of NY PLLC Admin | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,000.00 | 10/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175336760 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 10/07/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,384.00 | 10/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336665 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 10/06/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724926 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,569.00 | 10/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175336939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,632.00 | 10/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175336966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $900.00 | 10/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175337301 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 10/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719587 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 10/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740818 |
| Principal investigator 1 | Celgene Corporation | $30,500.00 | 09/30/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, PLLC | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1222305740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,042.00 | 09/29/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247790 |
| Principal investigator 1 | MEDIVATION LLC. | $1,050.00 | 09/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742864 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 09/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756595 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 09/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228757245 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,169.00 | 09/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247709 |
| Principal investigator 1 | Janssen Research & Development, LLC | $632.00 | 09/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,803.00 | 09/08/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336622 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,536.00 | 09/08/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 09/05/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,692.00 | 09/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336659 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 09/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755641 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 09/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755940 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 09/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756086 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,245.06 | 08/31/2025 | Non-covered Recipient Entity Associated Medical Professionals - Urology | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930193 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409222 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409226 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409234 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409268 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409292 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409294 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409426 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409468 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409470 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,396.65 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,348.00 | 08/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247899 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,421.00 | 08/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337395 |
| Recipient | PFIZER INC. | $3,200.00 | 08/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727571 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $1,450.00 | 08/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230630 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $3,000.00 | 08/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230635 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $15,000.00 | 08/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY, PLLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,154.00 | 08/18/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247825 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/18/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727027 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/17/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719797 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892396 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892401 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,100.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892405 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892409 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892413 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $750.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892416 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,520.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892420 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892424 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892428 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892432 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,100.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892446 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,520.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892450 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $750.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892454 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,600.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892457 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 08/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892461 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,718.00 | 08/11/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,482.00 | 08/11/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336849 |
| Principal investigator 1 | PFIZER INC. | $138,623.66 | 08/09/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,346.00 | 08/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,800.00 | 08/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 08/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337389 |
| Principal investigator 1 | PFIZER INC. | $138,623.66 | 08/07/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,600.00 | 08/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336571 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $520.00 | 08/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409284 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $338.00 | 08/01/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409356 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 08/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743022 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 08/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755430 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 08/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756695 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 08/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756974 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 08/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228757031 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726624 |
| Principal investigator 1 | Epizyme, Inc. | $2,224.80 | 07/28/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, Pllc | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184282140 |
| Principal investigator 1 | Epizyme, Inc. | $3,337.20 | 07/28/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, Pllc | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184282142 |
| Principal investigator 1 | Epizyme, Inc. | $1,112.40 | 07/28/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, Pllc | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184282144 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,811.00 | 07/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175248085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,380.00 | 07/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,568.00 | 07/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336865 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,744.00 | 07/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337419 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/28/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727163 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/21/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $825.00 | 07/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336875 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,669.00 | 07/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337478 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/18/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724924 |
| Principal investigator 1 | Epizyme, Inc. | $1,939.00 | 07/17/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, Pllc | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184282138 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 07/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 07/14/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247840 |
| Recipient | PFIZER INC. | $330.00 | 07/11/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727513 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/09/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723780 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,617.00 | 07/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640270 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/08/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,211.00 | 07/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,887.00 | 07/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,307.00 | 07/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 07/01/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247881 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742931 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754948 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755986 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756458 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756816 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756862 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 07/01/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228757234 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $520.00 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute LLC | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408294 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,516.00 | 06/30/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336826 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,360.00 | 06/27/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $165.00 | 06/25/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175248058 |
| Recipient | Dendreon Pharmaceuticals LLC | $500.00 | 06/24/2025 | Covered Recipient Physician | ProvONE | No dispute reported | 06/30/2026 | 1247891628 |
| Recipient | Dendreon Pharmaceuticals LLC | $250.00 | 06/24/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $954.00 | 06/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175337525 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $500.00 | 06/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636392 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,000.00 | 06/18/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636396 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,572.00 | 06/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175254973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,264.00 | 06/16/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,204.00 | 06/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175336889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 06/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175337081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,112.00 | 06/09/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 06/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,211.00 | 06/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,632.00 | 06/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336681 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,179.00 | 06/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175337272 |
| Recipient | Dendreon Pharmaceuticals LLC | $500.00 | 06/05/2025 | Covered Recipient Physician | ProvONE | No dispute reported | 06/30/2026 | 1247891480 |
| Recipient | Dendreon Pharmaceuticals LLC | $2,130.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891484 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891488 |
| Recipient | Dendreon Pharmaceuticals LLC | $2,130.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891492 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891496 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891500 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891504 |
| Recipient | Dendreon Pharmaceuticals LLC | $8,520.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891508 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,242.50 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891511 |
| Recipient | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891514 |
| Recipient | Dendreon Pharmaceuticals LLC | $2,130.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891518 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891523 |
| Recipient | Dendreon Pharmaceuticals LLC | $473.33 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891526 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891530 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891534 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891539 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891543 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,014.29 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891546 |
| Recipient | Dendreon Pharmaceuticals LLC | $473.33 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891550 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,242.50 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891554 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,242.50 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891558 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891562 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891567 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891570 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891574 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891578 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891581 |
| Recipient | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891585 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,014.29 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891589 |
| Recipient | Dendreon Pharmaceuticals LLC | $473.33 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891593 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,242.50 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891596 |
| Recipient | Dendreon Pharmaceuticals LLC | $250.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891600 |
| Recipient | Dendreon Pharmaceuticals LLC | $473.33 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891606 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,460.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891610 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891614 |
| Recipient | Dendreon Pharmaceuticals LLC | $5,720.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891618 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,460.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891622 |
| Recipient | Dendreon Pharmaceuticals LLC | $101.43 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891626 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $6,390.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891946 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891950 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $6,390.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891974 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891978 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891982 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891986 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,520.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891990 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891994 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $9,940.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247891998 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $6,390.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892002 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892007 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,840.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892011 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892014 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892019 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892022 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892026 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,100.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892030 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,840.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892034 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892038 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892042 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,260.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892047 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892050 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892057 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892062 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,260.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892066 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892069 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $9,940.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892074 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,100.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892077 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,840.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892080 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,970.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892084 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,840.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892087 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,920.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892095 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892099 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,720.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892116 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,920.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892130 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,420.00 | 06/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | ProvONE | No dispute reported | 06/30/2026 | 1247892177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,482.00 | 06/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175336338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,314.00 | 05/30/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336916 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/30/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754443 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753918 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 05/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,787.68 | 05/27/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 05/27/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247994 |
| Principal investigator 1 | Janssen Research & Development, LLC | $318.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,015.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,264.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336649 |
| Principal investigator 1 | Janssen Research & Development, LLC | $159.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $865.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337229 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337296 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,600.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175337463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,034.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337489 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722572 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722968 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778808 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228780857 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790214 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790940 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791065 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791186 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791335 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791376 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791499 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791650 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792106 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792355 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792526 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792952 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793001 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793171 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793236 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793284 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/26/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 05/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336675 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 05/23/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337265 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 05/20/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,596.00 | 05/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,517.00 | 05/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336266 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,114.00 | 05/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,263.00 | 05/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337002 |
| Principal investigator 1 | Janssen Research & Development, LLC | $492.00 | 05/19/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337235 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 05/19/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723260 |
| Principal investigator 1 | PFIZER INC. | $138,623.67 | 05/19/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228759343 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,142.00 | 05/16/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 05/16/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 05/16/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175337541 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $4,773.25 | 05/15/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242060287 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 05/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175248046 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 05/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336258 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,650.00 | 05/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336345 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,569.00 | 05/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336542 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,652.00 | 05/12/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336799 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/12/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751771 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/09/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751775 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 05/09/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $158.00 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,393.84 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,338.00 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $948.00 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247868 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248009 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 05/08/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248031 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $786.00 | 05/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634277 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722906 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724368 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724512 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228780061 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789818 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789826 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789895 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790599 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790711 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790766 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790836 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791504 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793017 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793272 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793277 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793317 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793511 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 05/05/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793515 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,772.47 | 04/30/2025 | Non-covered Recipient Entity ASSOCIATE MEDICAL PROFESSIONALS LLC | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1185546945 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/30/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753710 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752043 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,716.00 | 04/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,055.00 | 04/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 04/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337310 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,757.00 | 04/25/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,246.00 | 04/24/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175255046 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/21/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752856 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/19/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752320 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/19/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755977 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 04/11/2025 | Non-covered Recipient Entity Associated Medical Professionals of NY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926735 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,930.00 | 04/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632896 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $18,951.00 | 04/09/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,499.00 | 04/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336549 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,782.00 | 04/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,533.00 | 04/04/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,243.00 | 04/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336308 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,616.00 | 03/31/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,703.00 | 03/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175337257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 03/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336697 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 03/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 03/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336980 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,200.00 | 03/21/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337412 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,193.24 | 03/19/2025 | Non-covered Recipient Entity ASSOCIATE MEDICAL PROFESSIONALS LLC | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | No dispute reported | 06/30/2026 | 1185546943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,135.00 | 03/17/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175254888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,113.00 | 03/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $159.00 | 03/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336743 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 03/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336810 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 03/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337121 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,034.00 | 03/13/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337512 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $437,962.70 | 03/12/2025 | Non-covered Recipient Entity ASSOCIATE MEDICAL PROFESSIONALS LLC | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185546939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,700.00 | 03/11/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247816 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/11/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754439 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 03/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 03/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336383 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,812.00 | 03/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336833 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,400.00 | 03/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336986 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,910.00 | 03/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337532 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/10/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753426 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/10/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,940.00 | 03/07/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,718.00 | 03/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175336735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,730.00 | 03/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175337009 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,015.00 | 03/06/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337520 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,169.00 | 03/03/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,485.00 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,744.00 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336634 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720119 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774111 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774319 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774581 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774622 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774709 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774743 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775001 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775029 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775290 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775489 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775753 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775870 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776065 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776789 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777749 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777759 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778042 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778100 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786063 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786088 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786933 |
| Principal investigator 1 | MEDIVATION LLC. | $279.50 | 03/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228787233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,924.00 | 02/28/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336332 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 02/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 02/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 02/21/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247773 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,110.00 | 02/21/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247947 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 02/21/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $632.00 | 02/21/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248039 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,750.00 | 02/21/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175255070 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 02/19/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751592 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 02/18/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753915 |
| Principal investigator 1 | PFIZER INC. | $138,623.67 | 02/18/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755697 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175336958 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,632.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,632.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,264.00 | 02/17/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175337503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,150.00 | 02/13/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175247845 |
| Principal investigator 1 | PFIZER INC. | $4,957.83 | 02/12/2025 | Non-covered Recipient Entity Associated Medical Professionals of NY PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228750332 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,551.84 | 02/11/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175248090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,895.00 | 02/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $59,843.00 | 02/10/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175337349 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/10/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753590 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/08/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753131 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 02/08/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754368 |
| Principal investigator 1 | AstraZeneca UK Limited | $70,643.99 | 02/05/2025 | Non-covered Recipient Entity ASSOCIATE MEDICAL PROFESSIONALS LLC | A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) | No dispute reported | 06/30/2026 | 1185546941 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724534 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774352 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774509 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774812 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775022 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775285 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776458 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776462 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776939 |
| Principal investigator 1 | MEDIVATION LLC. | $750.00 | 02/04/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786057 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 02/03/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175255004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $865.00 | 02/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175336284 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,418.00 | 02/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175336923 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,638.00 | 02/03/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337357 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 01/30/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753714 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 01/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754035 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 01/29/2025 | Non-covered Recipient Entity Associated Medical Professionals of New York | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755288 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,213.20 | 01/29/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176624925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,631.00 | 01/28/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175247691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,882.00 | 01/27/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175336498 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175336973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 01/24/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175337157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,365.00 | 01/14/2025 | Non-covered Recipient Entity Assocd Medcl Professionals Of Ny Pllc Admn | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175254966 |
| Principal investigator 1 | Epizyme, Inc. | $1,550.64 | 01/08/2025 | Non-covered Recipient Entity Associated Medical Professionals Of Ny, Pllc | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184282136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50,975.00 | 01/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175337132 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 01/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775734 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 01/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776015 |
| Principal investigator 1 | MEDIVATION LLC. | $1,443.00 | 01/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776525 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 01/02/2025 | Non-covered Recipient Entity ASSOCIATED MEDICAL PROFESSIONALS OF NY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785604 |